BetterLife Pharma Appoints Chief Medical Officer to Lead Migraine Drug Development
BetterLife Pharma (BETRF) announced the appointment of Mahan Chehrenama as its chief medical officer, tasked with leading clinical development for BETR-001. The drug is a non-hallucinogenic neuroplastogen being developed to treat migraine and other headache disorders. The company expects to file an Investigational New Drug (IND) application in the first quarter of 2027. Chehrenama brings expertise as a neurologist and headache specialist, which is expected to strengthen BetterLife Pharma's drug development strategy.
Topics: Clinical Development Pharmaceuticals